The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
 
Luke Nordquist
Stock and Other Ownership Interests - Clarity Pharmaceuticals
Travel, Accommodations, Expenses - Fusion Pharmaceuticals
 
Eva Lengyelova
Employment - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Daniel Saltzstein
No Relationships to Disclose
 
David Josephson
No Relationships to Disclose
 
Gregg Franklin
Employment - New Mexico Cancer Center
Stock and Other Ownership Interests - New Mexico Cancer Center
Consulting or Advisory Role - Varian Medical Systems
Speakers' Bureau - Bayer
Travel, Accommodations, Expenses - Bayer
 
Glynn Morrish
Consulting or Advisory Role - Clarity Pharmaceuticals
 
Othon Gervasio
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Robert Miller
Employment - Clarity Pharmaceuticals; Hubro Therapeutics; Scancell Ltd.
Stock and Other Ownership Interests - Hubro Therapeutics (Inst)
Consulting or Advisory Role - Clarity Pharmaceuticals; Scancell Ltd.
Travel, Accommodations, Expenses - Hubro Therapeutics; Scancell Ltd.
 
Neal Shore
Employment - GenesisCare
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow